BURLINGTON, Mass., Dec. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the Asia Pacific dental biomaterial market will grow moderately through 2023 as the aging population, increasing adoption of dental implant procedures and growing awareness of dental biomaterials all spur procedure volumes. Growth will be particularly rapid in underdeveloped markets such as China and India, where rising disposable incomes will bring dental procedures within reach for a larger proportion of the population.
Other key findings from Decision Resources Group's coverage of the Asia Pacific dental biomaterial market:
- Developed South Korean market: Although the Chinese market generated the majority of revenue in the Asia Pacific dental biomaterial market in 2014 due to its large population, the South Korean market is the most developed. Less stringent regulations in the country have resulted in a wide availability of dental biomaterial products, and manufacturers have made strong efforts to promote their products in the country.
- Pricing declines: Pricing declines will be particularly notable in China, where more low-cost local manufacturers are entering the market, aided by China's new policy favoring domestic manufacturing. By contrast, price declines will be minimal in South Korea, where prices are already very low due to a high presence of local manufacturers and a developed market.
- Tissue regeneration products: Tissue regeneration products represent a niche market in the Asia Pacific region. These products are viewed as less essential than bone graft substitutes (BGS) or dental membranes and are generally priced much higher, which has limited their use, particularly in China.
Comments from Decision Resources Group Analyst Susan Weng:
- "Competitors that offer both BGS and dental membranes are at an advantage because these products are often used in combination. As a result, more manufacturers are looking to expand their product portfolios. For example, ZH-BIO offers a popular dental membrane product in China and is anticipated to enter the synthetic BGS market in 2015 or 2016."
Comments from Decision Resources Group Analyst David Lee:
- "Strict regulatory barriers in some Asia Pacific countries have restricted the availability of dental biomaterials. For example, allografts—including nonproprietary allografts and demineralized bone matrices—are used very rarely in China, Australia and Japan due to strict regulations and concerns surrounding the use of human tissue. A very stringent regulatory process in China in general has also slowed the launch of new products in the country."
- Susan Weng and David Lee have written Medtech 360 reports on this subject entitled Chinese Markets for Dental Biomaterials 2015 and Asia Pacific Markets for Dental Biomaterials 2015, respectively.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group